Mandatory, cost-driven switching from originator etanercept...

  • Main
  • 2018 / 11
  • Mandatory, cost-driven switching from originator etanercept...
Annals of the Rheumatic Diseases 2018 / 11

Mandatory, cost-driven switching from originator etanercept to its biosimilar SB 4 : possible fallout on non-medical switching

Cantini, Fabrizio, Benucci, Maurizio
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Annals of the Rheumatic Diseases
DOI:
10.1136/annrheumdis-2018-214757
Date:
November, 2018
File:
PDF, 114 KB
english, 2018
Conversion to is in progress
Conversion to is failed